APA (7th ed.) Citation

Dugbartey, G. J., Wonje, Q. L., Alornyo, K. K., Robertson, L., Adams, I., Boima, V., & Mensah, S. D. (2022). Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway. Frontiers in pharmacology, 13, 1. https://doi.org/10.3389/fphar.2022.850542

Chicago Style (17th ed.) Citation

Dugbartey, George J., Quinsker L. Wonje, Karl K. Alornyo, Louis Robertson, Ismaila Adams, Vincent Boima, and Samuel D. Mensah. "Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway." Frontiers in Pharmacology 13 (2022): 1. https://doi.org/10.3389/fphar.2022.850542.

MLA (9th ed.) Citation

Dugbartey, George J., et al. "Combination Therapy of Alpha-Lipoic Acid, Gliclazide and Ramipril Protects Against Development of Diabetic Cardiomyopathy via Inhibition of TGF-β/Smad Pathway." Frontiers in Pharmacology, vol. 13, 2022, p. 1, https://doi.org/10.3389/fphar.2022.850542.